Black Diamond Therapeutics shareholders approve officer liability limitation and elect directors

Black Diamond Therapeutics, Inc.

Shareholders approved Amendment to limit officer liability as permitted by Delaware law.
Prakash Raman and Mark A. Velleca elected as Class I directors to serve until 2027.
PricewaterhouseCoopers LLP ratified as independent auditor for FY2024.
Certificate of Amendment filed and effective June 6, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.